{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:20:43Z","timestamp":1783412443361,"version":"3.54.6"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.esmoop.2022.100480","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T18:34:45Z","timestamp":1650652485000},"page":"100480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Duration of treatment in oncology clinical trials: does the duration change when the same drug moves from the experimental arm to the control arm?"],"prefix":"10.1016","volume":"7","author":[{"given":"A.","family":"Haslam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Thawani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2022.100480_bib1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.drudis.2020.11.011","article-title":"Development and economic trends in anticancer drugs licensed in the UK from 2015 to 2019","volume":"26","author":"Lythgoe","year":"2021","journal-title":"Drug Discov Today"},{"issue":"15","key":"10.1016\/j.esmoop.2022.100480_bib2","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/cncr.29397","article-title":"Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer","volume":"121","author":"Lo","year":"2015","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100480_bib3","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/annonc\/mdz060","article-title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer","volume":"30","author":"Blumenthal","year":"2019","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2022.100480_bib4","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2013.53.0204","article-title":"Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients","volume":"32","author":"Prasad","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100480_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2016.02.012","article-title":"Strength of validation for surrogate end points used in the US Food and Drug Administration\u2019s approval of oncology drugs","author":"Kim","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2022.100480_bib6","article-title":"Trends of clinical outcomes with sorafenib in randomized controlled trials for patients with treatment-na\u00efve advanced hepatocellular carcinoma","volume":"39","author":"Brown","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100480_bib7","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/bjc.2015.56","article-title":"Development and economic trends in cancer therapeutic drugs: a 5-year update 2010-2014","volume":"112","author":"Savage","year":"2015","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100480_bib8","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2022.100480_bib9","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100480_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0030","article-title":"Assessment of outcomes associated with the use of newly approved oncology drugs in medicare beneficiaries","volume":"4","author":"Green","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100480_bib11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11948-011-9265-3","article-title":"Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications","volume":"18","author":"Lexchin","year":"2012","journal-title":"Sci Eng Ethics"},{"key":"10.1016\/j.esmoop.2022.100480_bib12","article-title":"Industry sponsorship and research outcome","volume":"2","author":"Lundh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100480_bib13","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2021.3046","article-title":"The oncologic drugs advisory committee votes of April 2021\u2014implications for the fate of accelerated approval","volume":"7","author":"Powell","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:26:51Z","timestamp":1761856011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922000990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2059702922000990"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100480","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duration of treatment in oncology clinical trials: does the duration change when the same drug moves from the experimental arm to the control arm?","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100480"}}